A seven-day triple therapy exhibits similar efficacy as 14-day therapy to eliminate infection caused by Helicobacter pylori (H. pylori) without 23S rRNA point mutation, says a study published in Medicine. Researchers undertook this observational study to explore the success rate of seven and 14 days of triple therapy for eliminating H. pylori without point mutation.

Medical records of people who underwent dual priming oligonucleotide-based polymerase chain reaction (DPO-PCR) were reviewed. The study recruited 366 participants without point mutations (A2142G and A2143G) as assessed by DPO-PCR. Evaluation of the eradication success rate and adverse events were done. The success rates of 7-day and 14-day triple therapy in intention to treat analysis and in the per-protocol analysis is shown in Table 1:

The adverse event rates demonstrated no vital differences between the two groups. In individuals without point mutation based on DPO-PCR results, the seven-day triple therapy was found to have comparable efficacy as 14-day triple therapy. Also, the seven-day triple therapy is a cost-effective approach, concluded the study authors.